Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Objectives: To evaluate the human abuse potential of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist recently approved by the US Food and Drug Administration for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Methods: Nondependent, recreational stimulant users able to distinguish phentermine HCl 60 mg from placebo in a drug discrimination test were randomized in a four-period, double-blind, crossover design to receive single doses of pitolisant 35.6 mg (therapeutic dose), pitolisant 213.6 mg (supratherapeutic dose), phentermine HCl 60 mg, and placebo. The primary endpoint was maximum effect (Emax) on the 100-point Drug Liking (“at this moment”) visual analog scale. Results: In 38 study completers (73.7% male; 65.8% white; mean age, 33.3 years), mean Drug Liking Emax was significantly greater for phentermine versus pitolisant 35.6 mg (mean difference, 21.4; p < 0.0001) and pitolisant 213.6 mg (mean difference, 19.7; p < 0.0001). Drug Liking Emax was similar for pitolisant (both doses) and placebo. Similarly, for key secondary measures of Overall Drug Liking and willingness to Take Drug Again, mean Emax scores were significantly greater for phentermine versus pitolisant (both doses) and similar for pitolisant (both doses) versus placebo. The incidence of adverse events was 82.1% after phentermine HCl 60 mg, 72.5% after pitolisant 213.6 mg, 47.5% after pitolisant 35.6 mg, and 48.8% after placebo administration. Conclusions: In this study, pitolisant demonstrated significantly lower potential for abuse compared with phentermine and an overall profile similar to placebo; this suggests a low risk of abuse for pitolisant. Clinical Trial Registration: ClinicalTrials.gov NCT03152123. Determination of the abuse potential of pitolisant in healthy, nondependent recreational stimulant users. https://clinicaltrials.gov/ct2/show/NCT03152123.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“Other safety assessments included vital signs measurements, physical examination findings, clinical laboratory test results, electrocardiogram parameters, and Columbia-Suicide Severity Rating Scale (C-SSRS) score [35].”
MethodThe International Classification of Sleep Disorders: Diagnostic and Coding Manual
Daroff, R. B. (1991) · Neurology · doi:10.1212/wnl.41.1.160 · Cited by 5,014
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733 · cited 1×
“amphetamines, opioids, ethanol, nicotine, and cocaine) [25, 26] and wake-promoting agents (i.”
The International Classification of Sleep Disorders
Greenblatt, D. W. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530270020006 · Cited by 1,559
The brain on drugs: from reward to addiction
Volkow, N. D., & Morales, M. (2015) · Cell · doi:10.1016/j.cell.2015.07.046 · Cited by 1,306 · cited 1×
“amphetamines, opioids, ethanol, nicotine, and cocaine) [25, 26] and wake-promoting agents (i.”
Histamine in the Nervous System
Haas, H. L., Sergeeva, O. A., & Selbach, O. (2008) · Physiological Reviews · doi:10.1152/physrev.00043.2007 · Cited by 1,228 · cited 1×
“Histamine activates wake-promoting neurons including norepinephrine neurons in the locus coeruleus, acetylcholine neurons in the pons and forebrain, and serotonin neurons in the dorsal raphe nucleus [58]; however, as noted above, histamine does not increase dopamine release in the nucleus accumbens [24, 27].”
BackgroundMartin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943 · cited 13×
“Peak scores on the ARCI scales were significantly different for pitolisant (both doses) compared with phentermine and not different for pitolisant relative to placebo (Table 3), with the exception of the dysphoria (LSD) scale, on which mean Emax for pitolisant 213.6 mg was significantly greater than that for placebo a…”
BackgroundMethodInfluentialMethylphenidate: Its Pharmacology and Uses
CHALLMAN, T. D., & LIPSKY, J. J. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)64618-1 · Cited by 553
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 529 · cited 1×
“the human nucleus accumbens, a brain region associated with rewarding effects and abuse [50].”
BackgroundScammell, T. E. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1500587 · Cited by 504
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial
Dauvilliers, Y., Bassetti, C., Lammers, G. J., Arnulf, I., Mayer, G., Rodenbeck, A., Lehert, P., Ding, C.-L., Lecomte, J.-M., & Schwartz, J.-C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70225-4 · Cited by 362
Self-citationSzakacs, Z., Dauvilliers, Y., Mikhaylov, V., Poverennova, I., Krylov, S., Jankovic, S., Sonka, K., Lehert, P., Lecomte, I., Lecomte, J.-M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30333-7 · Cited by 338
Self-citationThe histamine H3 receptor: from discovery to clinical trials with pitolisant
Schwartz, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01286.x · Cited by 318 · cited 2×
“Pitolisant is a first-in-class medication for the treatment of narcolepsy, with a novel mechanism of action [21, 22].”
BackgroundSelf-citationLin, J.-S., Dauvilliers, Y., Arnulf, I., Bastuji, H., Anaclet, C., Parmentier, R., Kocher, L., Yanagisawa, M., Lehert, P., Ligneau, X., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.003 · Cited by 269
Self-citationLigneau, X., Perrin, D., Landais, L., Camelin, J.-C., Calmels, T., Berrebi‐Bertrand, I., Lecomte, J., Parmentier, R., Anaclet, C., Lin, J., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111039 · Cited by 255
Self-citationAn evaluation of the abuse potential of modafinil using methylphenidate as a reference
Jasinski, D. R. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400107 · Cited by 238 · cited 1×
“400, or 800 mg) compared with placebo, but the overall pharmacologic profile (including responses on the ARCI Amphetamine scale) indicated lower abuse potential for modafinil compared with methylphenidate [51].”
BackgroundMethylphenidate Abuse and Psychiatric Side Effects
Morton, W. A., & Stock, G. G. (2000) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v02n0502 · Cited by 214
Stroke and methamphetamine use in young adults: a review
Lappin, J. M., Darke, S., & Farrell, M. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316071 · Cited by 191
Carter, L. P., Henningfield, J. E., Wang, Y. G., Lu, Y., Kelsh, D., Vince, B., & Sellers, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118796814 · Cited by 186 · cited 2×
“the abuse potential of solriamfetol appeared to be similar to or lower than that of phentermine [40].”
BackgroundResultMaski, K. P., Steinhart, E., Williams, D. N., Scammell, T. E., Flygare, J., McCleary, K., & Gow, M. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6494 · Cited by 171
Histamine H3 Receptors and Sleep-Wake Regulation
Lin, J., Sergeeva, O. A., & Haas, H. L. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170134 · Cited by 151 · cited 1×
“Pitolisant functions as an antagonist/inverse agonist at H3 autoreceptors, which increases the synthesis and release of histamine and enhances histaminergic signaling in the brain [56].”
BackgroundClinical and practical considerations in the pharmacologic management of narcolepsy
Thorpy, M. J., & Dauvilliers, Y. A. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.10.002 · Cited by 148 · cited 2×
“stimulants, wake-promoting agents, and sodium oxybate) are controlled substances [7]; thus, there has been a need for effective pharmacologic options to treat narcolepsy that have reduced potential for abuse.”
BackgroundHodgkins, P., Shaw, M., Coghill, D., & Hechtman, L. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0286-5 · Cited by 147
Loland, C. J., Mereu, M., Okunola, O. M., Cao, J., Prisinzano, T. E., Mazier, S., Kopajtic, T., Shi, L., Katz, J. L., Tanda, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.022 · Cited by 144
Histamine: neural circuits and new medications
Scammell, T. E., Jackson, A. C., Franks, N. P., Wisden, W., & Dauvilliers, Y. (2019) · Sleep · doi:10.1093/sleep/zsy183 · Cited by 143 · cited 1×
“histaminergic signaling in the brain promotes wakefulness and suppresses non-REM and REM sleep [57].”
BackgroundFrishman, W. H., Del Vecchio, A., Sanal, S., & Ismail, A. (2003) · Heart Disease · doi:10.1097/01.hdx.0000080713.09303.a6 · Cited by 139
??-Hydroxybutyrate/Sodium Oxybate: Neurobiology, and Impact on Sleep and Wakefulness
Pardi, D., & Black, J. E. (2006) · CNS Drugs · doi:10.2165/00023210-200620120-00004 · Cited by 124
Winslow, B. T., Voorhees, K. I., & Pehl, K. A. (2007) · PubMed · Cited by 121
The Humanistic and Economic Burden of Narcolepsy
Flores, N. M., Villa, K. F., Black, J. E., Chervin, R. D., & Witt, E. A. (2016) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.5594 · Cited by 109
The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings
Black, J. E., Reaven, N. L., Funk, S. E., McGaughey, K. J., Ohayon, M. M., Guilleminault, C., Ruoff, C. M., & Mignot, E. J.-M. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.02.001 · Cited by 108
Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions
Wisor, J. P. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00139 · Cited by 103 · cited 1×
“modafinil and armodafinil) [11], pitolisant does not work primarily through dopamine and does not cause an increase in dopamine levels in the nucleus accumbens (the brain’s main reward center) [27].”
BackgroundPitolisant: First Global Approval
Syed, Y. Y. (2016) · Drugs · doi:10.1007/s40265-016-0620-1 · Cited by 101
Carter, L. P., Richards, B. D., Mintzer, M. Z., & Griffiths, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301146 · Cited by 98
Abuse liability assessment of atomoxetine in a drug-abusing population
Jasinski, D. R., Faries, D. E., Moore, R. J., Schuh, L. M., & Allen, A. J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.008 · Cited by 87
Research design strategies to evaluate the impact of formulations on abuse liability
McColl, S., & Sellers, E. M. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.01.015 · Cited by 67 · cited 1×
“Human abuse potential studies utilize validated measures of subjective drug effects that evaluate the propensity of drug liking, positive and reinforcing effects, willingness to take drug again, perceived drug value, and pharmacological effects that are similar in nature to drugs with known abuse potential [41].”
BackgroundUguen, M., Perrin, D., Belliard, S., Ligneau, X., Beardsley, P. M., Jm, L., & Schwartz, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12149 · Cited by 59 · cited 5×
“Furthermore, pitolisant partially counteracts the stimulant properties of cocaine, as demonstrated in an animal study [27].”
BackgroundInfluentialSelf-citationPharmacological management of narcolepsy with and without cataplexy
Kallweit, U., & Bassetti, C. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1323877 · Cited by 58 · cited 1×
“For most patients, the management of narcolepsy requires lifelong pharmacological treatment [7, 8].”
BackgroundUpdate on the treatment of narcolepsy: clinical efficacy of pitolisant
Calik, M. W. (2017) · Nature and Science of Sleep · doi:10.2147/nss.s103462 · Cited by 52 · cited 1×
“The minimal abuse potential observed for pitolisant, showing similarity to placebo, is consistent with its mechanism of action, which differs from that of other products used in the treatment of narcolepsy [55].”
ResultMcGuinness, T. M. (2006) · AJN American Journal of Nursing · doi:10.1097/00000446-200612000-00024 · Cited by 41
Comparative abuse liability of GHB and ethanol in humans.
Johnson, M. W., & Griffiths, R. R. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0031692 · Cited by 26 · cited 1×
“In a study of nondependent, recreational users of both ethanol and other sedative-hypnotics, drug liking was significantly greater for sodium oxybate (at doses up to 10 g/70 kg) compared with placebo; drug liking for sodium oxybate was similar to that for alcohol, whereas willingness to take the drug again was signifi…”
BackgroundEaton, T. A., Comer, S. D., Revicki, D. A., Trudeau, J., van Inwegen, R. G., Stauffer, J. W., & Katz, N. P. (2011) · Quality of Life Research · doi:10.1007/s11136-011-0012-7 · Cited by 26 · cited 1×
“Approximately 10-point difference between drugs was reported to be clinically meaningful for Drug Liking [42] and High Emax scores [43].”
BackgroundWhite, A. G., LeCates, J., Birnbaum, H. G., Cheng, W. Y., Roland, C. L., & Mardekian, J. (2015) · Journal of Opioid Management · doi:10.5055/jom.2015.0269 · Cited by 18 · cited 1×
“In a study of opioid medications, reductions in Overall Drug Liking Emax were significantly associated with lower rates of nonmedical use [44].”
BackgroundSchoedel, K. A., Addy, C., Chakraborty, B., Rosko, K., Dunbar, S. A., Maes, A. L., Chen, N., Stoch, S. A., Wagner, J. A., Chodakewitz, J., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d380d · Cited by 14
Chen, L., & Bonson, K. R. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2011.616972 · Cited by 13 · cited 1×
“The margin of 11 points was based on recommendations from a meta-analysis of eight abuse potential studies [37].”
MethodCardiovascular disease risk factors and symptoms among regular psychostimulant users
Darke, S. G., Torok, M. H., Kaye, S. S., & Duflou, J. A. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00158.x · Cited by 9
Cited by
Update on Persistent Excessive Daytime Sleepiness in OSA
Javaheri, S., & Javaheri, S. (2020) · Chest · doi:10.1016/j.chest.2020.02.036 · Cited by 122
Metadata
- Authors
- Setnik, B., McDonnell, M., Mills, C., Scart-Grès, C., Robert, P., Dayno, J. M., & Schwartz, J.-C.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-18
- Volume
- 43
- Issue
- 4
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W2981226218
- Cited by
- 189
- References
- 46
- FWCI
- 24.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.